Neonc Technologies Holdings, Inc. (NASDAQ:NTHI – Get Free Report) fell 15.7% during mid-day trading on Tuesday . The stock traded as low as $10.10 and last traded at $11.26. 39,700 shares were traded during trading, a decline of 11% from the average session volume of 44,725 shares. The stock had previously closed at $13.36.
Neonc Technologies Stock Performance
Neonc Technologies Company Profile
Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing.
Further Reading
- Five stocks we like better than Neonc Technologies
- Expert Stock Trading Psychology Tips
- Boeing Stock Upgraded After Beating Lockheed for Jet Deal
- What Are Treasury Bonds?
- 2 Reasons to Buy Apple Stock and 1 Significant Risk
- How to Choose Top Rated Stocks
- Salesforce: The Most Resilient Software Stock for Downturns
Receive News & Ratings for Neonc Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neonc Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
